0.3794

6.48% -0.0263

After Hours: .41 0.0306 +8.07%

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Discussions Forecast

Neumora Therapeutics Inc stock is traded at $0.3794, with a volume of 830.48K. It is down -6.48% in the last 24 hours and down -48.12% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Previous Close:

$0.4057

Open:

$0.3986

24h Volume:

830.48K

Relative Volume:

0.39

Market Cap:

$71.29M

Revenue:

Net Income/Loss:

$-222.39M

P/E Ratio:

-0.286

EPS:

-1.3268

Net Cash Flow:

$-193.40M

1W Performance:

-19.92%

1M Performance:

-48.12%

6M Performance:

-82.99%

1Y Performance:

-83.58%

1-Day Range:

$0.3658

$0.414

1-Week Range:

$0.3658

$0.5049

52-Week Range:

$0.3154

$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

(857) 760-0900

Address

260 ARSENAL PLACE, SUITE 1, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	0.3794	71.29M	0	-222.39M	-193.40M	-1.3268
VRTX Vertex Pharmaceuticals Inc	523.93	132.80B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.02	82.88B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	200.10	79.89B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	873.71	54.94B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	377.63	42.72B	5.76B	514.49M	1.10B	4.4813

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-16-26	Reiterated	H.C. Wainwright	Buy
Jun-16-26	Reiterated	Needham	Buy
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Mar-07-25	Downgrade	Stifel	Buy → Hold
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Oct 14, 2026